http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
윤상웅 대한의사협회 2019 대한의사협회지 Vol.62 No.3
Psoriasis is a chronic inflammatory disease. Medical therapy is the mainstay of the management of psoriasis, and the main target of psoriasis treatment is immunological dysregulation. Cyclosporine and methotrexate, the main conventional psoriasis treatments, usually lead to a Psoriasis Area and Severity Index (PASI) 75 response in 50% to 60% of patients, but show some organ toxicity. Biologics for psoriasis have recently become the main therapeutic agents for moderate to severe psoriasis unresponsive to conventional treatment. Tumor necrosis factor-α inhibitors were the first anti-psoriatic biologics to be developed, and also show good efficacy for psoriatic arthritis. Ustekinumab, the sole biologic designed for the inhibition of interleukin (IL)-12/23, has been most widely used for psoriasis in Korea. The main strength of ustekinumab is its relatively long treatment interval. IL-17 inhibitors have recently been introduced in Korea for psoriasis treatment. Secukinumab and ixekizumab are currently available IL- 17 inhibitors that block the development of psoriasis lesions in the downstream events of psoriasis pathogenesis. They have excellent therapeutic efficacy, with a PASI 90 response in up to 60%-70% of patients. Selective IL-23 inhibitors have been more recently introduced in our country. They have an excellent PASI 90 response, and a longer injection interval than IL-17 inhibitors. New immunological modulators such as phosphodiesterase inhibitors, tyrosine kinase 2 inhibitors, and janus kinase inhibitors are planned to be introduced for psoriasis treatment. These are small molecules that can be administered orally, and some patients who are reluctant to receive injection therapy are expected to favor these therapeutic agents.
자율운항선박 항계내 정박지 연계 입출항 전역경로 생성 고려사항 연구
윤상웅,김동함,김혜진,손준배,이서호,김세원 한국항해항만학회 2023 한국항해항만학회 학술대회논문집 Vol.2023 No.1
자율운항선박은 인공지능, 센서 및 통신 기술을 활용하여 스스로 운항하는 선박으로, IMO 자율화등급 3단계 이상의 자율운항선박을개발하여 선원의 개입을 최소화하기 위해 많은 연구가 진행 중이다. 항만에서는 스마트항만을 위한 연구와 함께 자율운항선박과 스마트항만간 연계를 통한 운항 효율성 향상이 주목받고 있다. 운항 효율성 향상을 위해 과거 항적 데이터 및 항만 Port-mis 데이터를 활용한 입출항 지원 연구가 진행되면서 자율운항선박이 통항량이 적은 시간에 항만에 도착할 수 있도록 스케쥴링 계획 및 이에 따른 전역경로 생성 연구가 진행되고 있다. 본 연구에서는 입출항 스케쥴링을 통해 자율운항선박 전역경로가 생성되어 운항 중 급작스런 통향량 증가나 다른 외부요인으로인해 정박지에서의 대기가 필요한 경우 정박지 대기를 고려한 자율운항선박의 전역경로를 생성에 대한 고려사항을 연구하였다.
윤상웅 대한의사협회 2015 대한의사협회지 Vol.58 No.10
Psoriasis is a life-long chronic relapsing dermatosis that shows waxing and waning of disease despite of a lot of conventional treatment. Severe psoriasis, usually defined by a psoriasis area and severity index (PASI) score of more than 10 and an area of involved skin of more than 10%, is a typical indication for biologic therapy. TNF-α inhibitors (etanercept, infliximab, and adalimumab) and an IL-12/23 inhibitor (ustekinumab) are the major biologics currently available for psoriasis. After the introduction of biologic treatment, many patients with severe psoriasis experience dramatic improvement of their disease without many side effects and are able to maintain a long-term remission period. Long-term follow up of the side effects of currently available biologics reveals no increase in adverse events compared with non-psoriatic individuals. However, the high cost of psoriasis biologics is a major remaining hurdle for the prescription of these agents to patients with severe psoriasis.